ALNY Alnylam Pharmaceuticals, Inc.

ALNY Alnylam Pharmaceuticals, Inc.

Healthcare · Biotechnology

Market read

Scan convergence 1 scan as of 2026-08-14 1 bear converging

POC $452.13 · VWAP $351.48 · -36.1% vs 12m avg buyer

collapse vol: expandinggaps: stablechurn: quiet as of

Insiders no data — outside the Form 4 poll — US-filer feed only (foreign filers report via MAR managers'-transactions notices)

Coverage

2 watchlists

Watchlists @biotech-scan@ibb

ALNY Price Structure

Loading chart…

Loading timeframes…

Peers

Every watchlist ALNY belongs to, members best 30-day change first — ALNY highlighted in place. Each pill: 30d change, 1d/7d, and a close spark over the last 30 calendar days (~21 sessions); hover for price, RSI, and the full chart.

@ibb
@biotech-scan

Next earnings ALNY reports in 72 days Oct 29

Last report Jul 30

Reported the quarter ending 2026-06-30: revenue $1.29B, diluted EPS $1.21, net income $164M (SEC filing, revenue corroborated by the desk's provider cache). Across the print the stock moved -28.3% (close before → first close after).

full note →

Against street estimates

How ALNY's reported EPS compared with analyst consensus. Street estimates are single-source vendor consensus (yfinance). Actuals are vendor consensus-basis EPS (often non-GAAP); edgarEps is GAAP diluted from filings — disputed flags large disagreement only. EPS only.

8 most recent of 9 quarters · newest report Jul 30 · projection Aug 17

Result
Jul 30 2.141.84 GAAP ≠ -14.2%Miss
Apr 30 1.471.99+35.3%Beat
Feb 12 1.501.25-16.5%Miss
Oct 30 '25 1.752.90 GAAP ≠ +66.1%Beat
Jul 31 '25 0.150.32 GAAP ≠ +119.6%Beat
May 1 '25 -0.37-0.01 GAAP ≠ +97.3%Beat
Feb 13 '25 -0.140.06+142.5%Beat
Oct 31 '24 -0.39-0.50 GAAP ≠ -26.7%Miss

News (last pull)

Headlines about ALNY from the desk's news pull — links go to the publisher. Not a desk read: the market read above is the desk's own.

pulled 18 days ago · Jul 31

Types
Jul 30 Catalyst ALNY earnings
Feb 16 Article Daily Actions